Marksans Pharma Ltd (BOM:524404)

Q4 2025 Marksans Pharma Ltd Earnings Call Transcript

May 20, 2025 / 11:30 AM GMT

Release Date Price: ₹236.65 (-6.61%)

Transcript

Key Points

Positve

Marksans Pharma Ltd (BOM:524404) achieved an all-time high in both revenue and profit, with operating revenue increasing by approximately 21% year on year.
The US market was a significant growth driver, experiencing a 35% increase in revenue year on year.
The OTC segment reached a record high revenue, crossing the 2000 crore mark, demonstrating successful expansion of the OTC product pipeline.
The company commercialized 58 SKUs and has about 79 more products in the pipeline, indicating strong future growth potential.
Marksans Pharma Ltd (BOM:524404) remains debt-free, with a cash balance of INR7,004 crore as of March 31, 2025, enhancing its financial stability.

Negative

The fourth quarter experienced a slower cough and cold season, impacting RX product sales.
There was a decline in EBITDA margin by 183 basis points due to increased employee and R&D expenses.
The company faced high freight costs in the first two quarters, which affected overall profitability.
Working capital days increased, leading to lower operating cash generation.
Uncertainty around US tariffs poses a potential risk to future profitability and market dynamics.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MARK.NS - Marksans Pharma Ltd
Q4 2025 Marksans Pharma Ltd Earnings Call
May 20, 2025 / 11:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the conference call to discuss Marks and Parma Q4 F 525 earnings call hosted by Elara Securities India Private Limited.

As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes.

Should you need assistance during this conference call, please signal an operator by pressing 0 on your touchtone phone.

Please note that this conference is being recorded. I now hand the conference over to Doctor Beno Pati Paraal from Elara Securities India Private Limited.

Thank you and over to you, sir.

--------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.